Fusion proteins and methods of treating complement dysregulation using the same
AssigneeAlexion Pharmaceuticals, Inc.
InventorsJulian Chandler, Christian Cobaugh, Keith Bouchard, Jeffrey Hunter
Life of this patent
Estimating the term…
Abstract
Described herein are fusion proteins that include two fragments of factor H, a fragment of factor H and an Fc domain, or a fragment of factor H, a fragment of CR2, and an Fc domain. The use of such proteins in methods of treatment for diseases mediated by alternative complement pathway dysmegulation.
Claims35
A fusion protein having the structure, from N-terminus to C-terminus:
- D1-L1-Fc-L2-D2,
- wherein D1 comprises a fragment of complement factor H (FH) and/or a fragment of CR2;
- L1 is absent or is an amino acid sequence of at least one amino acid;
- Fc is an Fc domain, such as an Fc receptor binding domain;
- L2 is absent or is an amino acid sequence of at least one amino acid;
- and
- D2 comprises a fragment of FH and/or a fragment of CR2,
- wherein D1 and D2 cannot both comprise a fragment of CR2.
4-5. (canceled)
7-8. (canceled)
10-20. (canceled)
(canceled)
A fusion protein comprising (a) a moiety comprising a fragment of complement receptor 2 (CR2);
- (b) a moiety comprising a fragment of complement factor H (FH);
- and (c) an anti-albumin VHH domain, wherein optionally (a), (b), and/or (c) may be fused by a linker.
25-49. (canceled)
(canceled)
53-56. (canceled)
58-75. (canceled)
(canceled)
(canceled)
84-86. (canceled)
88-89. (canceled)
94-104. (canceled)
Dependencies are inferred from the claim text.